Product Introduction: APLINT -5 MG

APLINT -5 MG is a widely prescribed oral antidiabetic medication manufactured by Ajantha. Composed of 5mg of Linagliptin, this tablet is indicated for glycemic control in adult patients diagnosed with Type 2 Diabetes Mellitus. When used alongside a balanced diet and regular physical exercise, it helps regulate blood glucose levels.

Primary Indications

• Management of Type 2 Diabetes Mellitus in adults for optimal glycemic control.
• Improving insulin secretion and restricting hepatic glucose production.
• Preventing post-prandial blood glucose spikes and stabilizing fasting blood sugar levels.

Clinical Benefits

• HbA1c Optimization: Assists in achieving and maintaining target HbA1c (glycosylated hemoglobin) levels.
• Weight Neutrality: Does not cause weight gain and is well-tolerated.
• Glucose-Dependent Action: Low risk of hypoglycemia when used as monotherapy.

Possible Side Effects

Common side effects may include:

• Headache, nasopharyngitis, or upper respiratory tract infection.
• Mild gastrointestinal issues (constipation, abdominal bloating, gas).
• Hypoglycemia (low blood sugar), especially when co-administered with sulfonylureas or insulin.

How to Take APLINT -5 MG

• Take the tablet once daily, preferably at the same time each day, with or without food.
• Swallow the tablet whole with a glass of water. Do not crush, chew, or split.
• Do not stop taking the drug abruptly without consulting your endocrinologist.

Mechanism of Action

APLINT -5 MG contains Linagliptin, which is a selective, competitive dipeptidyl peptidase-4 (DPP-4) inhibitor. It prevents the degradation of active incretin hormones (GLP-1 and GIP) by DPP-4, increasing active incretin levels. This stimulates insulin secretion and suppresses glucagon release from the pancreas in a glucose-dependent manner.

Safety Warnings

• Pancreatitis: Discontinue if persistent, severe abdominal pain occurs.
• Pregnancy & Nursing: Not recommended; insulin is typically the preferred therapy during pregnancy.
• Hepatic Impairment: Safe for use without dose adjustment in renal or hepatic impairment.

Patient Advice

• Always carry a rapid-acting source of sugar (like glucose powder or fruit juice) in case of hypoglycemia.
• Monitor your blood glucose levels regularly as advised by your doctor.
• Adhere to a structured diet and exercise plan for optimal therapeutic outcomes.

Fact Box

Drug Interactions

• Insulin & Sulfonylureas: Concomitant use increases the risk of hypoglycemia; lower doses may be required.
• Rifampin: May decrease linagliptin efficacy. Avoid co-administration.

User Feedback

• Patients report excellent control of their fasting and post-meal sugar levels, with a significant drop in HbA1c.
• Praised for its gentle action and low incidence of side effects.